Business
Avenue Therapeutics is a specialty pharmaceutical company focused on neurologic disease therapies, with ATX-04 and IV tramadol named as current product candidates.
Avenue Therapeutics reported $1.4M of revenue and a much narrower loss, but cash from ops stayed negative and equity fell.
The read at a glance✓ Audited against SEC data
- Business mix — Neurologic disease drug candidatesNote
- Revenue — Revenue rose from zero to $1.4MOK
- Losses — Net loss narrowed to $2.9MOK
- Cash — Cash from ops -$1.8MWatch
- Balance sheet — Equity fell 34.5%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Forensic screen unavailableNote
Latest filings
- 10-Q · Quarterly report2026-08-07
- 10-Q · Quarterly report2026-05-08
- 10-K · Annual report2026-03-30
- 8-K · Company announcement2026-02-23
- 8-K · Company announcement2025-12-31
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AVENUE THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.